Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-γ

Anticancer Research

Volumn 16, Issue 3 A, 1996, Pages 1145-1154

  Lumsden, Angela J ^a,c   Codde, James P ^a   Van Der Meide, Peter H ^b   Gray, Bruce N ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

^b TNO   (Netherlands)

^c University   (Australia)

Author keywords

Chemo immunotherapy; Doxorubicin; Interferon ; Interleukin 2; Tumour infiltrating lymphocytes

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DOXORUBICIN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; HELPER CELL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR IMMUNOLOGY;

ADENOCARCINOMA; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DOXORUBICIN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERFERON-GAMMA, RECOMBINANT; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; NEOPLASM TRANSPLANTATION; PHENOTYPE; RATS; RATS, INBRED STRAINS;

EID: 0029987431     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Lumsden AJ, Codde JP, Gray BN and van der Meide PH: Improved efficacy of doxorubicin by simultaneous treatment with interferon gamma and interleukin-2. In Vivo 6: 553-558, 1992.
2. Bold DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA, Hawkins MJ, Atkins MB, Ciobanu N. and Ellis TM: Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Res. 48: 4409-4416, 1988.
3. Isacson R, Kedar E, Barak V, Gazit Z, Yurim O, Kahchman I. Ben-Basset H. Biran S. Schlesinger M, Franks CR, Roest GJ, Palmer PA, and Shiloni. E: Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologie parameters and correlation with clinical response. Immunol Lett 33, 127-134,1992
4. Baseler MW and Urba WJ: Immunological monitoring and clinical trials of biological response modifiers. In: HM Pinedo, DL Longo and BA Chabner (eds). Cancer chemotherapy and biological response modifiers. Annual 12, pp 231-250, BV: Elsevier Science Publishers 1991.
5. Weiner LM, Padavic-Shaller K, Kitson J, Watts P, Krigel RL and Litwin S: Phase I evaluation of combination therapy with interleukin-2 and γ-interferon. Cancer Res 51: 3910-3918, 1991.
6. Aulitzky WE, Aulitzky W. Gastl G, Lanske B, Reitter J, Frick J. Tilg H, Berger M, Herold M and Huber C: Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced cell cancer. J Interferon Res 9: 425-433,1989.
7. Lumsden AJ, Codde JP, Gray BN and van der Meide PH: Prevention of myelosuppression does not improve the therapeutic efficacy of chemo-immunotherapy. Anticancer Res 12: 1725-1730, 1992.
8. Ghosh AK, Dazzi H, Thatcher N and Moore M. Lack of correlation between peripheral blood lymphokine activated killer (LAK) cell function and clinical response in patients with advance malignant melanoma receiving recombinant interleukin 2. Int J Cancer 43: 410-414, 1989.
9. Yeung RS, Vollmer C, Taylor DD, Palazzo J and Weese JL: Intra-tumoral rIL2-based immunotherapy in B16 melanoma. J Surg Res 53: 203-210, 1992.
10. Lauzon W. Yang H and Lemaire I: Comparative analysis of natural killer function in lung, spleen, and peripheral blood lymphocytes: evidence of differential characteristics. Reg Immunol 3: 145-150, 1991
11. Nakamura H, Ishiguro K and Mori T: Different immune functions of peripheral blood, regional lymph node, and tumour infiltrating lymphocytes in lung cancer patients. Cancer 62: 2489-2497, 1988
12. Black PL Phillips H, Tribble HR, Pennington R, Schneider M and Talmadge JE• Correlation of immunomodulatory and therapeutic activities of interferon and interferon inducers in metastalic disease J Cell Biochem 36, 377-392, 1988
13. Hutchinson GH, Heinemann D, Symes MO and Williamson RCN: Differential immune reactivity of tumour-intrinsic and peripheral blood lymphocytes against autoplastic colorectal carcinoma cells. Br J Cancer 44: 396-402, 1981
14. Underwood JCE: Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br J Cancer 30: 538-548, 1974.
15. Aaltomaa S, Lipponen P, Eskelinen M, Kosma V-M, Mann S, Alhava E and Syrjanen K: Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur Cancer 28A: 859-864, 1992.
16. Nakano T, Oka K, Takahashi T, Morita S and Arui T: Roles of Langerhans' cells and T-lymphocytes infiltrating cancer tissues in patients treated by radiation therapy for cervical cancer Cancer 70: 2839-2844, 1992.
17. Svennevig JL, Lunde OC, Holter J and Bjoryvik D: Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer 49: 375-377, 1985.
18. Hamlin IME: Possible host resistance in carcinoma of the breast, a histological study. Br J Cancer 22: 383-401, 1968.
19. Lipponen PK, Eskelinen MJ, Juahiainen K. Harju E and Terho R: Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer 29A: 69-75,1993.
20. Vose BM and Moore M: Human tumour-infiltrating lymphocytes: A marker of host response. Seminars in Hematology 22: 27-40, 1985.
21. Stotter H, Wiebke EA, Tomita S, Belldegrun A, Topalian S, Rosenberg SA and Lotze MT: Cytokines alter target cell susceptibility to lysis: II Evaluation of tumor infilatrating lymphocytes. J Immunol 142: 1767-1773, 1989.
22. Belldegrun A, Muul LM and Rosenberg SA: Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: Isolation, characterization and antitumor activity. Cancer Res 48: 206-214, 1988.
23. Rabinowich H. Cohen R, Bruderman I, Steiner Z and Klajman A: Functional analysis of mononuclear cells infiltrating into tumours: Lysis of autologous human tumour cells by cultured infiltrating lymphocytes. Cancer Res 47. 173-177,1987.
24. Lotzova E, Savary CA, Freedman RS, Edwards CL and Morris M: Comparison of recombinant interleukin-2-activated peripheral blood and tumour-infiltrating lymphocytes of patients with epithelial ovarian carcinoma: cytotoxicity, growth kinetics and phenotype. Cancer Immunol Immunother 31: 169-175, 1990.
25. Tomita, Y, Nishiyama, T, Fujiwara, M, and Sato, S Immunohistochemical detection of major histocompatibility complex antigens and quantitative analysis of tumour-infiltrating mononuclear cells in renal cell cancer. Br J Cancer 62: 354-359,1990.
26. Nouri AME, dos Santos AVL. Crosby D and Oliver RTD: Correlation between class I antigen expression and the ability to generate tumour infiltrating lymphocytes from bladder tumour biopsies. Br J Cancer 64: 996-1000, 1991.
27. Okada Y, Yahata G, Takeuchi S, Seidoh T and Tanaka K: A correlation between the expression of CD 8 antigen and specific cytotoxicity of tumour-infiltrating lymphocytes. Jpn J Cancer Res (Gann) 80: 249-256, 1989.
28. Maekawa R, Kitagawa T, Hojo K, Wada T and Sato K. Distinct antitumour mechanisms of recombinant murine interferon-gamma against two murine tumour models. J Interferon Res 8: 227-239, 1988.
29. Shimizu Y. Iwatsuki S, Herberman RB and Whiteside TL. Effects of cytokines on in vitro growth of tumour-infiltrating lymphocytes obtained from human primary and metastatic liver tumours. Cancer Immunol Immunother32: 280-288, 1991.
30. Fox BA, Spiess PJ, Kasid A, Pun R, Mule JJ, Weber JS and Rosenberg SA: In vitro and in vivo antitumour properties of a T cell clone generated from murine tumour infiltrating lymphocytes. J Biol Response Mod 9: 499-511, 1990.
31. Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerim C, Fossati-Bellani F and Parmiani G: Phenotype and functional analysis of lymphocytes infiltrating paediatric tumours. with a characterization of tumour phenotype. Cancer Immunol Immunother 34: 241-251,1992.
32. Niitsuma M, Golub SH, Edeistein R and Holmes EC: Lymphoid cells infiltrating human pulmonary tumours: effect of intralesional BCG injection. J Natl Cancer Inst 67: 997-1003, 1981.
33. Bohle A, Busemann E, Gerdes J, Ulmer AJ, Flad H-D and Jocham D: Long-term immunobiological effects of intravesical bacillus Calmette-Guerin against bladder carcinoma recurrences. Dev Biol Stand 77: 199-209, 1992
34. Bindon C, Czerniecki M, Ruell P, Edwards A, McCarthy WH. Harris R and Hersey P: Clearance rates and systemic effects of intravenously administered interleukin-2 (IL-2) containing preparations in human subjects. Br J Cancer 47: 123-133, 1983.
35. Haskill S, Becker S, Fowler W and Walton L: Mononuclear-cell infiltration in ovarian cancer. I. Inflammatory-cell infiltrates from tumour and ascites material. Br J Cancer 45: 728-736, 1982.
36. Haskill, S, Koren, H, Becker. S, Fowler. W, and Walton. L Mononuclear-cell infiltration in ovarian cancer. II. Immune function of tumours and ascites-derived inflammatory cells. Br J Cancer 45: 737-746,1982
37. Maley MAL, House AK, Jenkyn DJ and Agrez MV: Three new rat colon tumor cell lines from 1,2-dimethylhydrazine induced adenocarcinomas: Morphology, karyotype and clonogenicity Br J Exp Path 68: 719-726,1987.
38. Snedecor GW and Cochran WG: Statistical Methods. Ames: The Iowa State University Press, 1967.
39. Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L and Raus J: Phenotypic analysis of tumour-infiltrating lymphocytes from human breast cancer. Anticancer Res 12:1463-1466, 1992.
40. Ghosh AK and Moore M: Tumour infiltrating lymphocytes in cervical carcinoma. Eur J Cancer 11: 1910-1916. 1992.
41. Minderman H, Linssen PCM, Wessels JMC and Haanen C: Doxorubicin toxicity in relation to the proliferative state of human hematopoietic cells. Exp Hematol 79: 110-114,1991.
42. Evans R, Kamdar SJ, Duffy T and Edison L: Intratumour gene expression after adoptive immunotherapy in a murine tumour model. J Immunol 150. 177-184,1993.
43. Whiteside TL: Tumour-infiltrating lymphocytes as antitumour effector cells Biotherapy 5: 47-61, 1992.
44. Moy PM, Holmes EC and Golub SH: Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumours. Cancer Res 45: 57-60, 1985.
45. Miescher S, Whiteside TL, Carrel S and von Fliedner V: Functional properties of tumour-infiltrating and blood lymphocytes in patients with solid tumours: Effects of tumour cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136: 1899-1907, 1986.
46. Botha JH, Robinson KM, Ramchurren N, Reddi K and Norman RJ: Human esophageal carcinoma cell lines: Prostaglandin production, biologic properties, and behaviour in nude mice. J Natl Cancer Inst 76: 1053-1056, 1986.
47. Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warkinek R, Frei K, Hofer G and Fontana A: T-cell suppressor factor from human glioblastoma cells is a 125 Kd protein closely related to transforming growth factor beta. EMBO J 6: 1633-1636, 1987.
48. Rubin JT, Elwood LJ, Rosenberg SA and Lotze MT: Immunohistochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans. Cancer Res 49. 7086-7092 1989.
49. Whitwell HL, Hughes HPA, Moore M and Ahmed A: Expression of major histocompatibility antigens and leukocyte infiltration in benign and malignant human breast disease. Br J Cancer 49: 161-172, 1984.
50. Csiba A, Whitwell HL and Moore M: Distribution of histocompatibility and leukocyte differentiation antigens in normal human colon and in benign and malignant colonie neoplasms. Br J Cancer 50- 699-709, 1984.
51. Inoue H, Adachi M, Karimine N, Arinaga.S , Ueo H, Korenaga D and Akiyoshi T: Immunohistochemical analysis of lymphocyte subsets infiltrating gastric carcinoma after mitomycin C administration. Cancer Immunol Immunother 35 297-301, 1992.
52. Morton DL, Foshag LJ, Hoon DSB, Nizze A, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R and Irie RF: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216: 463-482. 1992.
53. Snyderman CH, Heo DS, Chen K, Whiteside TL and Johnson JT: T cell markers in tumour-infiltrating lymphocytes of head and neck cancer Head & Neck 11: 331-336, 1989.
54. Arinaga S, Akiyoshi T and Tsuji H: Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients. Cancer Res 46: 4213-4216, 1986.
55. Waldmann, TA The IL-2/IL-2 receptor system: A target foi rational immune intervention. Immunol Today 14: 264-270, 1993.
56. Velotti F, Stoppacciaro A, Ruco L, Tubaro A, Pettinato A, Morrone S, Napolitano T, Bossola PC, Franks CR, Palmer P, Pourreau CN, Piccoli M, Baroni CD, Frati L. Miano L and Santoni A: Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2. Cancer Res 51: 2456-2462, 1991.
57. Holter W, Grunow R, Stockinger H and Knapp W: Recombinant IFN-gamma induces rIL-2 receptors on human peripheral blood monocytes. J Immunol 136: 2171-2175,1986.
58. Holter W, Goldman Ck, Casabo L, Nelson DL, Greene WC and Waldmann TA: Expression of functional IL-2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J Immunol 138: 2917-2922, 1987
59. Siegel JP: Effects of interferon-gamma on the activation of human T lymphocytes. Cellular Immunol 111: 461472, 1988.
60. Maraskovsky E, Chen W and Shortman K: IL-2 and IFN-γ are two necessary lymphokines in the development of cytolytic T cells. J Immunol 143: 1210-1214, 1989.
61. Gullberg M and Smith KA: Regulation of T cell autocrine growth. T4+ cells become refractory to interleukin 2. J Exp Med 163: 270-284, 1986.
62. Cantrell DA and Smith KA: Transient expression of IL-2 receptors: Consequences for T cell growth. J Exp Med 158: 1985- 1990, 1983.
63. Shevach EM: Macrophages and other accessory cells In: WE Paul (ed), Fundamental Immunology, pp 71107, New York: Raven Press 1984.
64. Allavena P, Damia G, Colombo T, Maggioni D, D'Incalci M and Mantovani A: Lymphokine-activated killer (LAK) and monocytemediated cytotoxicity on tumour cell lines resistant to antitumour agents. Cellular Immunol 120: 250-258, 1989.
65. Ozzello L, Habif DV, De Rosa CM and Cantell K: Cellular events accompanying regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma. Cancer Res 52: 4571-4581,1992.
66. Zinkernagel RM and Doherty PC: MHC-restricted cytotoxic T cells: Studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction specificity, function and responsiveness. Adv Immunol 27: 51-177, 1979.
67. Tanaka K, Yoshioka T, Bieberich C and Jay G: Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Ann Rev Immunol 6: 359-380. 1988.
68. Wallich R, Bulbuc N, Hammerling GJ, Katzav S. Segal S and Feldman M: Abrogation of metastatic properties of tumour cells by de nevo expression of H-2K antigens following H-2 gene transfaction. Nature 315: 301-305, 1985.
69. Smith MEF, Marsh SGE, Bodmer JG, Gelsthorpe K and Bodmer WF: Loss of HLA-A. B. C allele products and lymphocyte functionassociated antigen 3 in colorectal neoplasia. Proc Natl Acad Sci USA 86: 5557-5561, 1989.
70. Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, Backmann R. Funke I and Riethmuller G: Frequent down regulation of major histocompatability Class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 51: 4712-4715, 1991.
71. Lopez-Nevot MA, Esteban F, Ferron A, Gutierrez J, Oliva MR, Romero C, Huelin C, Ruiz-Cabello F and Garrido F: HLA class I gene expression on human primary tumours and autologous metastases: Demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 59: 221-226, 1989
72. Tanaka K, Hayashi H, Hamada C, Khoury G and Jay G: Expression of major histocompatability complex class I antigens as a strategy for the potentiation of immune recognition of tumour cells. Proc Natl Acad Sci USA 83: 8723-8727, 1986.
73. Napolitano LA, Vogel J and Jay G: The role of major histocompatibility complex class I antigens in tumorigenesis: Future applications in cancer therapy. Biochim Biophys Acta 989: 153-162, 1989.
74. Pfizenmaier K, Bartsch H, Scheurich P, Seliger B, Ucer U, Vehmeyer K, and Nagel, GA Differential gamma-interferon response of human colon carcinoma cells: Inhibition of proliferation and modulation of immunogenicity as independent effects of gamma-interferon on tumour cell growth. Cancer Res 45: 3503-3509, 1985.
75. Weber JS and Rosenberg SA: Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res 48: 5818-5824, 1988.
76. Handgretinger R, Bruchelt G, Kimmig A, Lang P, Daurer B, Dopfer R. Treuner J and Niethammer D: In vitro and in vivo effect of interleukin-2 on 2,5-oligoadenylate synthetase activity of peripheral mononuclear blood cells. J Interferon Res 10: 75-82,1990.
77. Marley GM, Doyle LA, Ordonez JV, Sisk A, Hussain A and Yen R-WC: Potentiation of interferon induction of class I major histocompatibility complex antigen expression by human tumor necrosis factor in small cell lung cancer cell lines. Cancer Res 49: 6232-6236, 1989.
78. Pfizenmaier K, Scheurich P, Schluter C and Kronke M: Tumour necrosis factor enhances HLA-A, B, C and HLA-DR gene expression in human tumour cells. J Immunol 138: 975-980, 1987.
79. Chong AS-F, Boussy IA, Graf LH and Scuderi P: Stimulation of IFN-gamma, TNF-alpha, and TNF-beta secretion in TL-2 activated T cells: Costimulatory roles for LFA-1, LFA-2, CD44 and CD45 molecules. Cellular Immunol 144: 69-79, 1992.
80. Cohen PJ, Lotze MT, Roberts JR, Rosenberg SA and Jaffe ES: The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol 129: 208-216, 1987.
81. Zaloudik J, Moore M, Ghosh AK, Mechl Z and Rejthar A: DNA content and MHC class II antigen expression in malignant melanoma: Clinical course. J Clin Pathol 41: 1078-1084, 1988.
82. Pardoll DM: Cancer vaccines. Immunol Today 14: 310-316, 1993.